ANI PHARMACEUTICALS INC (ANIP) — insider trading
Health Care · NASDAQ
ANI PHARMACEUTICALS INC (ANIP) has 33 reported SEC Form 4 insider transactions in our data, including 22 open-market sales among the most recent 33 (latest 2026-09-29).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-29 | CAREY STEPHEN P. | Officer (SVP & CFO) | Open-market sale | 2,850 | $73.00 | $208.1K | Form 4 |
| 2026-09-15 | Lalwani Nikhil | Director, Officer (PRESIDENT & CEO) | Open-market sale | 5,400 | $71.00 | $383.4K | Form 4 |
| 2026-09-14 | Cook Meredith | Officer (SR. VP, GENERAL COUNSEL & SEC.) | Open-market sale | 500 | $70.79 | $35.4K | Form 4 |
| 2026-09-11 | Thoma Jeanne | Director | Open-market sale | 1,000 | $71.53 | $71.5K | Form 4 |
| 2026-08-31 | CAREY STEPHEN P. | Officer (SVP & CFO) | Open-market sale | 2,850 | $72.80 | $207.5K | Form 4 |
| 2026-08-25 | Lalwani Nikhil | Director, Officer (PRESIDENT & CEO) | Open-market sale | 5,400 | $74.30 | $401.2K | Form 4 |
| 2026-08-19 | Gosebruch Henry O | Director | Grant / award / vesting | 6,662 | — | $0 | Form 4 |
| 2026-08-13 | Cook Meredith | Officer (SR. VP, GENERAL COUNSEL & SEC.) | Open-market sale | 500 | $75.48 | $37.7K | Form 4 |
| 2026-08-10 | Gutwerg Ori | Officer (SVP, GENERICS) | Open-market sale | 3,162 | $77.00 | $243.5K | Form 4 |
| 2026-07-29 | CAREY STEPHEN P. | Officer (SVP & CFO) | Open-market sale | 2,850 | $81.36 | $231.9K | Form 4 |
| 2026-07-18 | Cook Meredith | Officer (SR. VP, GENERAL COUNSEL & SEC.) | Shares withheld for taxes / exercise cost | 2,466 | $79.20 | $195.3K | Form 4 |
| 2026-07-13 | Cook Meredith | Officer (SR. VP, GENERAL COUNSEL & SEC.) | Open-market sale | 500 | $81.84 | $40.9K | Form 4 |
| 2026-07-02 | CAREY STEPHEN P. | Officer (SVP & CFO) | Option exercise / conversion (derivative) | 3,313 | $49.51 | $164.0K | Form 4 |
| 2026-07-02 | CAREY STEPHEN P. | Officer (SVP & CFO) | Open-market sale | 3,313 | $86.00 | $284.9K | Form 4 |
| 2026-07-02 | CAREY STEPHEN P. | Officer (SVP & CFO) | Option exercise / conversion | 3,313 | $49.51 | $164.0K | Form 4 |
| 2026-06-29 | CAREY STEPHEN P. | Officer (SVP & CFO) | Open-market sale | 2,850 | $84.12 | $239.7K | Form 4 |
| 2026-06-12 | Cook Meredith | Officer (SR. VP, GENERAL COUNSEL & SEC.) | Open-market sale | 500 | $82.03 | $41.0K | Form 4 |
| 2026-06-08 | HAUGHEY THOMAS | Director | Open-market sale | 2,000 | $80.88 | $161.8K | Form 4 |
| 2026-06-05 | CAREY STEPHEN P. | Officer (SVP & CFO) | Option exercise / conversion (derivative) | 3,312 | $49.51 | $164.0K | Form 4 |
| 2026-06-05 | CAREY STEPHEN P. | Officer (SVP & CFO) | Open-market sale | 3,312 | $80.00 | $265.0K | Form 4 |
| 2026-06-05 | CAREY STEPHEN P. | Officer (SVP & CFO) | Option exercise / conversion | 3,312 | $49.51 | $164.0K | Form 4 |
| 2026-05-21 | HAUGHEY THOMAS | Director | Grant / award / vesting | 4,357 | — | $0 | Form 4 |
| 2026-05-21 | Leonard Matthew J | Director | Grant / award / vesting | 4,357 | — | $0 | Form 4 |
| 2026-05-21 | Pera Antonio R | Director | Grant / award / vesting | 4,357 | — | $0 | Form 4 |
| 2026-05-21 | TANNENBAUM RENEE P | Director | Grant / award / vesting | 4,357 | — | $0 | Form 4 |
| 2026-05-21 | Thoma Jeanne | Director | Grant / award / vesting | 4,357 | — | $0 | Form 4 |
| 2026-05-13 | Cook Meredith | Officer (SR. VP, GENERAL COUNSEL & SEC.) | Open-market sale | 500 | $78.16 | $39.1K | Form 4 |
| 2026-05-13 | Walsh Patrick D | Director | Open-market sale | 10,000 | $80.63 | $806.3K | Form 4 |
| 2026-05-12 | Gutwerg Ori | Officer (SVP, GENERICS) | Open-market sale | 2,772 | $79.50 | $220.4K | Form 4 |
| 2026-05-12 | Rowland Thomas Andrew | Officer (SVP, HEAD - ESTABLISHED BRANDS) | Open-market sale | 459 | $79.21 | $36.4K | Form 4 |
| 2026-05-11 | Lalwani Nikhil | Director, Officer (PRESIDENT & CEO) | Open-market sale | 55,000 | $77.57 | $4.27M | Form 4 |
| 2026-05-11 | Walsh Patrick D | Director | Open-market sale | 3,973 | $80.75 | $320.8K | Form 4 |
| 2026-04-13 | Cook Meredith | Officer (SR. VP, GENERAL COUNSEL & SEC.) | Open-market sale | 500 | $77.95 | $39.0K | Form 4 |
Ask the chat about ANIP's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ANI PHARMACEUTICALS INC (ANIP).
Last updated 2026-09-29 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.